Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Biswa Mohan Biswal is active.

Publication


Featured researches published by Biswa Mohan Biswal.


Integrative Cancer Therapies | 2013

Effect of Withania somnifera (Ashwagandha) on the Development of Chemotherapy-Induced Fatigue and Quality of Life in Breast Cancer Patients

Biswa Mohan Biswal; Siti Amrah Sulaiman; Hasanah Che Ismail; Hasmat Zakaria; Kamarul Imran Musa

Hypothesis. Withania somnifera is an herb with antioxidant, anti-inflammatory, anticancer, antistress, and adaptogenic properties. Previous studies have shown its antistress effects in animals. Traditional Indian medicine has used it for centuries to alleviate fatigue and improve general well-being. Methods. This is an open-label prospective nonrandomized comparative trial on 100 patients with breast cancer in all stages undergoing either a combination of chemotherapy with oral Withania somnifera or chemotherapy alone. The chemotherapy regimens were either taxotere, adriamycin, and cyclophosphamide or 5-fluorouracil, epirubicin, and cyclophosphamide. Withania somnifera root extract was administered to patients in the study group at a dose of 2 g every 8 hours, throughout the course of chemotherapy. The quality-of-life and fatigue scores were evaluated before, during, and on the last cycles of chemotherapy using the EORTC QLQ-C30 (Version 3), Piper Fatigue Scale (PFS), and Schwartz Cancer Fatigue Scale (SCFS-6). Results. The median age distributions in the study and control arm were 51 years (range = 36-70) and 50.5 years (range = 32-71), respectively. The majority (77%) of patients had stage II and III disease. Patients in the control arm experienced statistically significant higher estimated marginal means of fatigue score compared with the study group (P < .001 PFS, P < .003 SCFS-6). Furthermore, various symptom scales of the EORTC QLQ-C30 were statistically significant in 7 out of 18 symptoms in the intervention group compared with the control group (P < .001). The 24-month overall survival for all stages in study and control group patients were 72% versus 56%, respectively; however, the result was not significant (P = .176), at a median follow-up duration of 26 months. Conclusions. Withania somnifera has potential against cancer-related fatigue, in addition to improving the quality of life. However, further study with a larger sample size in a randomized trial is warranted to validate our findings.


Asia-pacific Journal of Clinical Oncology | 2017

Prognostic factors and survival rate of osteosarcoma: A single-institution study

Faisham Wi; Arman Zaharil Mat Saad; Laith N Alsaigh; Mat Z Nor Azman; Musa Kamarul Imran; Biswa Mohan Biswal; Venkata Mk Bhavaraju; Salleh Salzihan; Jaafar Hasnan; Aziz M Ezane; Nasir Ariffin; Mohamad Norsarwany; Mohamad G Ziyadi; Wan Sulaiman Wan Azman; Ahmad Sukari Halim; Zulmi W

Osteosarcoma is a highly malignant primary bone tumor. The study aim to evaluate the prognostic factors influencing the survival rate in our center.


Asian Journal of Surgery | 2003

Molecular Genetic Analysis of Anaplastic Pleomorphic Xanthoastrocytoma

Noor Azam Nasuha; Abd. Hamid Daud; Mazira Mohamad Ghazali; Abdul Aziz Mohamed Yusoff; Norafiza Zainuddin; Jafri Malin Abdullah; Samarenda Singh Mutum; Biswa Mohan Biswal; Ariff Ar; Sarina Sulong; Mohd Nizam Isa

A case of pleomorphic xanthoastrocytoma in a 10-year-old Malay boy is reported. The patient presented with headache and epilepsy. On computed tomography, a ring-enhancing low-density lesion was observed in the left fronto-temporal area. During surgery, a cystic tumour containing serous fluid was found and almost totally removed. Histologically, the tumour exhibited marked pleomorphism of oval and spindle-shaped cells intermixed with uni- and multinucleated giant cells, and xanthomatous cells with foamy cytoplasm. The tumour displayed pericellular reticulin and periodic acid-Schiff positive granules. Focally, six mitotic characters per 10 high-power fields were seen, and necrosis was confined only to the inner lining of the cyst. Mutational analysis showed that a frameshift mutation (a 4-bp deletion) in the p53 gene had occurred in codons 273 and 274 of exon 8. No mutation was detected in the p16 gene. No allelic loss and/or loss of heterozygosity were observed on chromosome 10 using microsatellite marker D105532. The patient was treated with postoperative radiotherapy because of histological anaplasia and the presence of residual tumour. The patient showed marked neurological recovery after a follow-up period of 2 years.


Indian Journal of Medical and Paediatric Oncology | 2010

Intra-abdominal desmoplastic small round cell tumor: Presentation of four cases and review of the literature

Biswa Mohan Biswal; Venkatesh R Naik; Syed Ejaz Shamim

Desmoplastic small round cell tumor (DSRCT) of the abdomen is a recently identified aggressive neoplasm. Very few cases have been reported in the literature. Thus, the treatment guidelines are yet to be defined. The role of chemotherapy, radiotherapy and surgery is evolving. We treated four cases of DSRCT involving the abdomen using combination chemotherapy and/or tumor cytoreductive surgery. There were two men and two women. The chemotherapy drugs consisted of cisplatin, adriamycin, etoposide, ifosphamide, vincristine and cyclophsophamide. All patients achieved meaningful partial response to chemotherapy, which maintained for 6–9 months. There were very minimal chemotherapy-related complications. At the time of reporting, the median survival time was 15 months. Thus, DSRCT is an aggressive intra-abdominal tumor with excellent chemoresponsiveness, but relapse is frequent.


Journal of Cancer Science & Therapy | 2011

Pilot Study on Continuous Hyperfractionated Accelerated Radiotherapy(CHART) and High Dose Rate Brachytherapy in Locally Advanced CervicalCancer

Biswa Mohan Biswal; Nik Min Ahmad; Zainal Abidin Hanafia; Ahmad Zakaria; Nor Hayati Othman

Background: Fractionated external beam radiotherapy followed by intracavitary brachytherapy is the mainstay of treatment in cervical cancer. Due to long radiotherapy course, patients in developing countries default effective radiotherapy. Treatment break or discontinuance leads to treatment failure. Continuous hyperfractionated accelerated radiotherapy (CHART) is an altered fractionation scheme used to reduce overall treatment time, overcome tumor repopulation thus could be an option in cervical carcinoma. Methods: Twenty-five histopathological documented locally advanced cervical carcinoma (FIGO stage IB2- IVA) were treated with 42Gy/30fractions external radiotherapy over 10-day period at an inter-fraction interval of 6 hours using CHART technique. Following CHART, patients were subjected to high dose rate brachytherapy to a dose schedule of 9Gyx2 at weekly interval. The response to above radiotherapy protocol and morbidity pattern was evaluated. Results: All patients completed planned CHART external radiotherapy. The median follow-up was 32-months with a pelvic control rate of 68% and 24-month overall survival was 72%. The most common acute toxicity in CHART technique was fatigue (64%) and diarrhea (52%), the late effects being rectal bleeding (2-cases), subcutaneous fibrosis (1-case), spinal pain (1-case). Conclusion: CHART technique is an effective and well tolerated technique in locally advanced cervical cancer at a cost of manageable fatigue and diarrhea. Further investigation involving large number of patients is warranted to evaluate this technique.


Supportive Care in Cancer | 2003

TOPICAL APPLICATION OF HONEY IN THE MANAGEMENT OF RADIATION MUCOSITIS: A PRELIMINARY STUDY

Biswa Mohan Biswal; Ahmad Zakaria; Nik Min Ahmad


BMC Cancer | 2011

Diagnosis delay of breast cancer and its associated factors in Malaysian women

Bachok Norsa'adah; Krishna Gopal Rampal; Mohd Amin Rahmah; Nyi Nyi Naing; Biswa Mohan Biswal


Medical Oncology | 2013

Gender-specific association of NFKBIA promoter polymorphisms with the risk of sporadic colorectal cancer

Shing Cheng Tan; Mohd Shafi’i Mohd Suzairi; Abdul Aziz Ahmad Aizat; Mustapha Mohd Aminudin; Mohd Shahpudin Siti Nurfatimah; Venkata Murali Krishna Bhavaraju; Biswa Mohan Biswal; Ravindran Ankathil


The Medical journal of Malaysia | 2004

Assessment of Knowledge, Attitude and Exposure to Oncology and Palliative Care in Undergraduate Medical Students

Biswa Mohan Biswal; Zakaria A; Baba Aa; Ja'afar R


Neurologia Medico-chirurgica | 2002

Intramedullary Spindle Cell Hemangioendothelioma of the Thoracic Spinal Cord

Jafri Malin Abdullah; Samerendra Singh Mutum; Noor Azam Nasuha; Biswa Mohan Biswal; Ariff Ar

Collaboration


Dive into the Biswa Mohan Biswal's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar

Faisham Wi

Universiti Sains Malaysia

View shared research outputs
Top Co-Authors

Avatar

Zulmi W

Universiti Sains Malaysia

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Ahmad Zakaria

Universiti Sains Malaysia

View shared research outputs
Top Co-Authors

Avatar

Ariff Ar

Universiti Sains Malaysia

View shared research outputs
Top Co-Authors

Avatar

Nik Min Ahmad

Universiti Sains Malaysia

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge